The Lung and Upper Aerodigestive Cancer Research Group conducts and supports research on the prevention and early detection of lung and head and neck cancers, as well as new approaches to clinical prevention studies including cancer immunoprevention.
Phase 0/I/II Cancer Prevention Clinical Trials Program
The group jointly administers the Phase 0/I/II Cancer Prevention Clinical Trials Program evaluating new agents, surrogate biomarkers, and technologies to identify premalignant lesions, and related cancers.
Lung Cancer-COPD Program
Additionally, the Lung Cancer-COPD Program, a collaboration between NCI and the National Heart, Lung, and Blood Institute (NHLBI) to understand the commonalities linking these two tobacco-related diseases, is administered here in partnership with NHLBI’s Division of Lung Diseases.
PREVENT Cancer Preclinical Drug Development Program
The group works closely with the PREVENT program, housed in the Chemopreventive Agent Development Research Group, on developing new animal models for ovarian cancer that can be used to evaluate chemopreventive agents, as well as developing new agents for breast and gynecologic cancers.